Basic and clinical studies on T-3262 in urology

T-3262, a new pyridone-carboxylic acid, was evaluated basically and clinically in the urological field. 1) Minimal inhibitory concentrations (MICs) of T-3262 were compared with those of norfloxacin, ofloxacin and ciprofloxacin using 189 clinical isolates from urinary tract infections (UTI). The antibacterial activity of T-3262 was as high as or even higher than those of the three other drugs against all species studied. 2) The concentration of T-3262 in the prostate after oral administration of 150 mg was studied. The concentration in the prostatic tissue, 2 and 4 hours after administration, was 0.120±0.075 μg/g (mean ± SE) and 0.245±0.079 μg/g, respectively. Similarly, the concentration in the prostatic fluid, 1, 2 and 4 hours after administration, was O.047±0.014 μg/ml, 0.111±0.080 μg/ml and 0.033±0.014 μg/ml, respectivery. 3) Forty-one patients with UTI were treated by oral administration of T-3262 at a dosage of 75 or 150 mg two or three times daily for 3-14 days. According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 100%(5/5) in acute uncomplicated cystitis and 60.0%(15/25) in complicated UTI. 4) No drug-related side effects, including abnormal laboratory findings, were observed in any of the 40 cases.